0
Editor's Correspondence |

Importance of Distinguishing Supported and Unsupported Off-label Drug Use

Surrey M. Walton, PhD; Glen T. Schumock, PharmD, MBA; G. Caleb Alexander, MD, MS; David Meltzer, MD, PhD; Randall S. Stafford, MD, PhD
Arch Intern Med. 2010;170(7):657-658. doi:10.1001/archinternmed.2010.69.
Text Size: A A A
Published online

Extract

In their recent commentary, Largent et al1 propose guidance to help clinicians distinguish between well-supported and unsupported off-label prescribing. In 2008, we published a related analysis using nationally representative data from a survey of office-based physicians to identify the frequency of unsupported off-label use of specific therapies.2 We identified medications for which research on off-label use is most urgently needed based on recency of market entry, known adverse effects, high medication cost, high levels of promotional expenditures, and high volume of uses with insufficient evidence. Largent et al1 discussed these same features with the exception of promotional efforts, a factor we consider crucial, given the potential impact of marketing on prescribing. Among the top 25 prioritized medications, antidepressants (escitalopram, trazodone, sertraline, bupropion, amitriptyline, and venlafaxine), antipsychotics (quetiapine and risperidone), and anxiolytics/sedatives (zolpidem, lorazepam, and clonazepam) were prominent. Given the complexities that clinicians face in assessing the evidence base supporting different therapies,3 particular vigilance may be appropriate when using these treatments.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Female Pattern Hair Loss. Int J Endocrinol Metab 2013;11(4):e9860.
Jobs
brightcove.createExperiences();